Upload
dwain-hodges
View
224
Download
0
Tags:
Embed Size (px)
Citation preview
Serdar Bulun, MD
George H. Gardner Professor of Clinical Gynecology
Chief, Division of Reproductive Biology ResearchDepartment of Obstetrics and Gynecology
Northwestern University, Chicago, IL
Pathogenesis of Pain in Endometriosis
ENDOMETRIOSIS• Common cause of chronic pelvic pain and infertility
• Polygenic inheritance and multifactorial etiology
• 3-6 million women of reproductive age are affected in the USA
• Responsible for 10%-15% of all hysterectomies performed in the USA
GLANDS
STROMA
MEDICAL TREATMENT OPTIONS
• Oral contraceptives
• GnRH analogs
• Progestins
• Aromatase inhibitors
• Selective Progesterone Receptor Modulators
ANDROSTENEDIONE
aromatase
adrenaladrenal
OVARYOVARYANDROSTENEDIONE
GnRH-aOC
aromatase inhibitor
FAT AND SKIN
ANDROSTENEDIONE ESTRONE
3-Estradiol
1-Estradiol
2-Estradiol
CHOLESTEROL
StAR
ENDOMETRIOSIS
aromatase
Endometrium fromDisease-free Women
Endometrium fromWomen with Endometriosis
Endometriosis
1
2
3
PRECURSOR
E
E
PGE2
PGE2
PGE2
PRECURSOR aromataseESTROGEN
PRECURSOR aromatase ESTROGEN
COX-2PGE2PRECURSOR
COX-2 PGE2PRECURSOR
COX-2 PGE2PRECURSOR
Noble, et al, JCEM, 1996; Ota, et al, 2001
SF1
SF1
CYTOPLASM
Src
DNATarget geneNRE
PROTEIN PRODUCTSOF TARGET GENES
BIOLOGIC FUNCTIONe.g., DIFFERENTIATION
NUCLEUS
NR
NRP
membranereceptor
MAPK
TF
classical
nonclassical
NRP
NRP
steroidreceptor
NUCLEAR RECEPTORS (NR)
NRP
orphan nuclear receptor
fold
dif
fere
nce
(m
RN
A b
y re
al-t
ime
PC
R)
ERαERβ TotalPR
PR-B
ENDOMETRIUM (TISSUE)
OVARIAN ENDOMETRIOMA (TISSUE)
1
2
3
4
5
6
7
8
9
108.9
142.4 9.3
14.1
Xu Q et al, BOR 2007
SF
1 m
RN
A
0.2
0.4
0.6
0.8
1.0
E-IUM E-OSIS
>12,000
NUCLEAR RECEPTORS AND ENDOMETRIOSIS
EPIGENETIC DEFECTS IN ENDOMETRIOSIS
SF-1 HYPOMETHYLATION
Methylation of CpG islands at promoters and gene expression
Unmethylated CpG site
Methylated CpG site
exon1 exon2 exon3
exon1 exon2 exon3
on
off
Promoter CpG island
SF1 GENE PROMOTER
NORMAL SUBJECTS
PATIENTS WITHENDOMETRIOSIS
exon1 exon2
exon1 exon2
Transcription coactivatingcomplex
HDAC1
exon1 exon2
exon1 exon2
exon1 exon2
exon1 exon2
SF1on
offMeCP2SF1
ENDOMETRIOSIS
ENDOMETRIUM
Xu Q et al, JCEM 2007
mSin3A
SF1 PROMOTER IS NOT METHYLATED IN ENDOMETRIOSIS
unmethylated CpG island
methylated CpG island
ROLE OF SF-1 IN
ESTROGEN
PRODUCTION
1
2
3
4
G
E-IUM E-OSIS
LRH
-1 m
RN
A (
amol
/mg
18S
)
0.5
1
1.5
2.0
E
E-IUM E-OSIS
P45
0aro
m m
RN
A (
amol
/mg
18S
)
*
un-detectable
FS
F-1
mR
NA
(am
ol/m
g 18
S)
0.2
0.4
0.6
0.8
1.0
E-IUM E-OSIS
*
StA
R m
RN
A
(am
ol/m
g 18
S)
20
40
60
80
100
120
140
160
E-IUM E-OSIS
A*p<0.01
P45
0scc
mR
NA
(am
ol/m
g 18
S)
0.5
1
1.5
2.0
2.5
B
E-IUM E-OSIS
*p<0.001
E-IUM E-OSIS
3HS
DB
II (
amol
/mg
18S
)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
C
*p<0.01
p<0.001 p<0.001 p<0.05
*
E-IUM E-OSIS
P45
0c17
mR
NA
(am
ol/m
g 18
S)
0.05
0.1
0.15
0.2
0.25
0.3
0.35
D
*p<0.05
Attar and Tokunaga et al, JCEM, 2009
PERITONEAL ENDOMETRIOSIS
0
5
10
15
20
25
30
StA
R (
amol
/mg
18S
)H
SD
3BI (
amol
/mg
18S
)
HS
D3B
II (a
mol
/mg
18S
)
*
*
*
*
*
*p= 0.032
PGE2: - + - +E-IUM E-IUM E-OSIS E-OSIS
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.00
0.05
0.10
0.15
0.20
0.25
PGE2: - + - +E-IUM E-IUM E-OSIS E-OSIS
PGE2: - + - +
E-IUM E-IUM E-OSIS E-OSIS
*
E-IUM E-IUM E-OSIS E-OSIS
PGE2: - + - +
P45
0aro
m (
amol
/mg
18S
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2 *
*
*p= 0.030
*p= 0.05 *p= 0.012
E-IUM E-IUM
PGE2: - + - +
0.00
0.02
0.04
0.06
0.08
0.10
0.12
P45
0c17
(am
ol/m
g 18
S)
*
*
E-OSIS E-OSIS
*p= 0.042
*
*
E-IUM E-IUM
P45
0scc
(am
ol/m
g 18
S)
0
2
4
6
8
10
12
14
PGE2: - + - +E-OSIS E-OSIS
*p= 0.048
A B
C D
E F
OVARIAN ENDOMETRIOTIC STROMAL CELLS
Attar and Tokunaga et al, JCEM, 2009
HO
O
O
O
OH
HO
O
HO
C
CH3
O
OH
HO
O
O
C
CH3
O
O
C
CH3
OOH
HO
C
CH3
O
HO
OH
cholesterol
MITOCHONDRION
pregnenolone
17-hydroxypregnenolone
dehydroepiandrosterone
StAR
P450scc
P450c17
P450c17
androstenedione testosterone
estrone ESTRADIOL
17-hydroxyprogesterone
PROGESTERONE
P450c17
P450c17
P450arom P450arom
HSD3B2
HSD3B2
HSD3B2 HSD17B1
HSD17B1
6
12
34
5
9
7
810
1112
13
14 1516
17
18
19
21 2022
23
252427
26
++++++++++
ENDOMETRIOSIS
nmol/L
pmol/L
estroneandrostenedione
estradiol
aromatase
PGE2COX-2
++adrenal
AA
++
ENDOMETRIOSIS TISSUE
aromatase inhibitor
CHOLESTEROL
++
Attar and Tokunaga, et al, JCEM, 2009Takayama et al, Fertil Steril, 1998Ailawadi et al, Fertil Steril, 2004Amsterdam et al, Fertil Steril, 2005
Noble et al, JCEM, 1997Zeitoun et al, Mol Endo, 1999Tamura et al, JBC, 2002Tamura et al, JCEM, 2002Tamura et al, JCEM, 2002
IL-1VEGF
++SF1
StAR
scc
3-HSD-2
17-OH-lase
17/20-lyase
Hypothalamus
Pituitary FSHLH
Postmenopausal on AI
Ovary
Peripheral Tissues
Endometriosis
Aromatase
PeripheralAromatase
No Follicular
Aromatase
AI
Aromatase
Takayama et al, Fertil Steril, 1998; Ailawadi et al, Fertil Steril, 2004; Soysal et al, Human Reproduction, 2004; Amsterdam et al, Fertil Steril, 2005; Attar and Bulun Fertil Steril, 2006
Follicle Development
Prememopausal on AI(Hypothetical)
Aromatase
FSHLH
AromataseE2
Aromatase
AI
PeripheralAromatase
Prememopausal on AI+ OC or P
Aromatase
Aromatase
PeripheralAromatase
AI
OC P
GnRHa
AromataseE2
FSHLH
Pre- and Post-treatment Pain Scores (n=10)
0
5
10
0
5
10
Ave
rage
Pai
n S
core
Baseline post-treatmentp=0.0028
PREMENOPAUSAL WOMEN TREATED WITH LETROZOLE AND NORETHINDRONE ACETATE
Ailawadi, et al, Fertil Steril, 2004
Before Treatment
PREMENOPAUSAL WOMEN TREATED WITH LETROZOLE AND NORETHINDRONE ACETATE
Ailawadi, et al, Fertil Steril, 2004
Before Treatment
PREMENOPAUSAL WOMEN TREATED WITH LETROZOLE AND NORETHINDRONE ACETATE
Ailawadi, et al, Fertil Steril, 2004
After Treatment for 6 Months
PREMENOPAUSAL WOMEN TREATED WITH LETROZOLE AND NORETHINDRONE ACETATE
Ailawadi, et al, Fertil Steril, 2004
Mild hot flushes (2/day – 1/week)
Sleepiness
Mood swings
Decreased libido
No bone loss
SIDE EFFECTS
TREATMENT RECOMMENDATIONS• An aromatase inhibitor is the treatment of choice for persistent
postmenopausal endometriosis
• A combination of an aromatase inhibitor with an OC or GnRH analog may be used to treat endometriosis-related pain not responding to conventional treatments
• Await results of randomized studies for the routine use of aromatase inhibitors for premenopausal endometriosis, uterine leiomyomata and ovulation induction
EPIGENETIC DEFECTS IN ENDOMETRIOSIS
ER HYPOMETHYLATION
Bisulfite sequencing: ERβ promoter
Exon 0N
Exon 0N
TSS +1
100bpBisulfite sequence
Classical CpG island 556bp
Exon 1
-163 -158 -133 -131 -129 -126 -123 -119 -107 -104 -90 -74 -48 -163 -158 -133 -131 -129 -126 -123 -119 -107 -104 -90 -74 -48
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
-163 -158 -133 -131 -129 -126 -123 -119 -107 -104 -90 -74 -48 -163 -158 -133 -131 -129 -126 -123 -119 -107 -104 -90 -74 -48
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
44481bp
Exon 0K
10957bp
NORMAL SUBJECTS
PATIENTS WITHENDOMETRIOSIS
P< 0.001
ERgene
MeCP2
HDAC1mSin3a
Pr 0N
CpG island
Pr 0K
Methylated
Pr 0N
CpG island
Pr 0K
Unmethylated
+CBP
ENDOMETRIUM ENDOMETRIOSIS
ROLE OF ER IN
PROSTAGLANDIN
PRODUCTION
PROSTAGLANDIN AND ESTRADIOLBIOSYNTHETIC PATHWAYS
ANDROSTENEDIONE
ESTRONE
ESTRADIOL
HSD17B1
Aromatase
PGE2
PGH2
ARACHIDONIC ACID
COX-2
mPGES-1
PHOSPHOLIPIDSPLA2
?
PROSTAGLANDIN AND ESTRADIOLBIOSYNTHETIC PATHWAYS
ANDROSTENEDIONE
ESTRONE
ESTRADIOL
HSD17B1
Aromatase
PGE2
PGH2
ARACHIDONIC ACID
COX-2
mPGES-1
PHOSPHOLIPIDSPLA2
ER
IL-1VEGF
ROLE OF ER IN
PROGESTERONE
RESISTANCE
MensesProliferativeendometrium
E2
Secretoryendometrium
E2 + P
17-HSD-2: _ ++++_
(Epithelial)
E2 E1:_ ++++
_
Bulun SE, et al, MCE, 2006
HO
OH
HO
O
HSD17B2
PROGESTERONE
HO
OH
HSD17B2
+
PROGESTERONE
progesterone resistance
EUTOPICENDOMETRIUM
ENDOMETRIOSIS
E1
E2
E1E2
HO
O
Zeitoun, et al, JCEM, 1998Yang, et al, Mol Endo, 2001
T47
D
Cycle Day: 3 6 10 12 14 16 18 24 26
PR-B
PR-A
EUTOPICENDOMETRIUM
PR-B
PR-AENDOMETRIOSIS
Attia, et al, JCEM, 2000
ERgene
Prom 0N
CpG island
ER
PRgene
PR-APR-B
ER
+
ER
ENDOMETRIOSISMeCP2
HDAC1mSin3a
ER
ER
PR-BPR-A
ER ER ER
ERgene
Prom C Prom A
Trukhacheva et al, JCEM, 2009
Bulun, SE, NEJM 2009Cheng, Y, JCEM, 2008
BIG PICTURE
PGE2
estradiolCHOLESTEROL
SF1COX-2
ER ER
PR
retinoic acid
estroneHSD17B2 arom
methylation
methylation
Bulun et al, NEJM, 2009
Bulun, SE, NEJM 2009
Menses
ERSF1
Painful menses
OTHERS
SURVIVAL AND IMPLANTATION OF ENDOMETRIOTIC CELLS
FAILURE OF CELLS TO IMPLANT
peritoneum peritoneum
NORMAL ENDOMETRIOSIS
methylatedpromoter
unmethylatedpromoter
CELLS CLEARED BY IMMUNE SYSTEM
+
ROLE OF EPIGENETICS INMECHANISM OF
ENDOMETRIOSIS
PREVIOUS:Jianfeng ZhouLi MengSijun Yang Juan FangDavid LangoiBilgin GuratesSiby SebastianMitsutoshi TamuraKhaled ZeitounKazuto TakayamaGeorge AttiaLuis NobleSantanu DebGonca ImirRegina MartinStephen ThungVeysel FenkciMasashi DemuraSanober AminWen CaoHiroki UtsunomiyaErkut AttarBertan YilmazNewton LeeAmy HakimHideki TokunagaHiroshi IshikawaCarrie RichardsonMegan O’Hallaran
Julie KimRomana NowakDebu ChakravartiHironobu SasanoTakashi SuzukiNobuo YaegashiKunihiro OkamuraEvan SimpsonMitch DowsettSeema KhanMichael PutmanAsgi FazleabasAlan JohnsDavid RedwineKirk NeelyBerenice MendoncaMakio ShozuErkut Attar
CURRENT:Chris Brooks John CoonsDong ChenYouhong ChengMatthew DysonXia LuoErica MarshDiana MonsivaisIrene MoyAntonia NavarroMary Ellen PavoneKerry PearsonEmily SuPing YinHong Zhao
BULUN LAB COLLABORATORS
NICHDR37-38691U54-40093SUPPORT